Patritumab deruxtecan |CAS 2227102-46-5|DC Chemicals

Cas No.:	2227102-46-5
pH value:	Corresponds to reference standard: PASS
Non-reduced CE-SDS:	>95%
SEC-HPLC:	>95%
Isoelectric Point:	Corresponds to reference standard
Osmolality:	Corresponds to reference standard: PASS
Peptide mapping:	Corresponds to reference standard: PASS
N-terminal sequence:	Corresponds to reference standard: PASS

Description:	Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) consisting of a fully human anti-HER3 IgG1 monoclonal antibody Patritumab (HY-P99275) attached to a topoisomerase I inhibitor payload via a tetrapeptide-based cleavable linker. Patritumab deruxtecan shows anticancer activity[1].
In Vitro:	Patritumab deruxtecan exhibits activity against breast cancer cells expressing HER3 mutations, regardless of HER2 overexpression [1]. Patritumab deruxtecan (0-100 nM) binds to the surface of all HER3 mutant variants and HER3WT MDA-MB-231 cells in a concentration-dependent manner but does not bind to HER3EV cells [1].
References:	[1]. Koyama K, et al. Patritumab deruxtecan (HER3-DXd), a novel HER3 directed antibody drug conjugate, exhibits in vitro activity against breast cancer cells expressing HER3 mutations with and without HER2 overexpression. PLoS One. 2022 May 3;17(5):e0267027.

Cat. No.	Product name	Field of application
A1061	Osemitamab Biosimilar(Anti-CLDN18.2 Reference Antibody)	Osemitamab is an IgG1 antibody targeting to human claudin-18.2. Osemitamab consists of human-Mus musculus monoclonal TST001 γ1-chain, disulfide with human-Mus musculus monoclonal TST001 κ-chain, dimer (ACI). Osemitamab in combination with Capecitabine (HY-B0016) and Oxaliplatin (HY-17371), can be used for G/GEJ cancer study.
A1060	Muromonab Biosimilar（Anti-CD3 Reference Antibody）	Muromonab is a monoclonal antibody targeting the CD3 receptor. Muromonab can block all cytotoxic T cell function. Muromonab also as an immunosuppressant agent given to reduce acute solid organ transplant rejection.
A1059	Atoltivimab Biosimilar（Anti-EBOV Reference Antibody）	Atoltivimab (REGN3470), or maftivimab/odesivimab (Inmazeb) is the first Food and agent Administration (FDA)-approved monoclonal antibody to target Zaire ebolavirus (EBOVs) infection.
A1058	Navivumab Biosimilar（Anti-HA Reference Antibody）	Navivumab (CT-P23) is an influenza A virus hemagglutinin HA monoclonal antibody. neutralizes H1, H2, H5, and H9 influenza A viruses by binding to the stem fusion domain in HA2.
A1057	Anti-IAV Reference Antibody Biosimilar
A1056	Odesivimab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Odesivimab is a human monoclonal antibody, targeting Ebola virus glycoprotein with a KD value of 7.74 nM for recombinant histidine-tagged Makona strain Ebola virus glycoprotein ectodomain protein. Odesivimab can be used in research of Ebola virus infection.
A1055	Cosfroviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Cosfroviximab (c13C6-FR1) is a mouse/human chimeric monoclonal antibody against Ebola virus glycoprotein (EBOV-GP).
A1054	Porgaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Porgaviximab is a monoclonal antibody that can be used Ebola infection research.
A1053	Larcaviximab Biosimilar（Anti-Zaire Ebola virus Reference Antibody）	Larcaviximab (c4G7-N) is an IgG1 kappa anti-Ebola virus glycoprotein chimeric monoclonal antibody.
A1052	Romlusevimab Biosimilar（Anti-Spike RBD Reference Antibody）	Romlusevimab (BRII-198) is a neutralizing recombinant human IgG1 monoclonal antibody against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).